Advertisement
Journal Home
Search for

Volume 30, Issue 10, Pages 1211-1218 (October 2002)


View previous. 15 of 16 View next.

CD34 is a specific marker of mature murine mast cells

Erin Drew, Helen Merkens, Shierley Chelliah, Regis Doyonnas, Kelly M McNagnyCorresponding Author Informationemail address

Received 21 February 2002; received in revised form 17 May 2002; accepted 3 June 2002.

Abstract 

Objective

CD34 is a 90- to 120-kDa cell surface sialomucin that is widely used for the enrichment of human hematopoietic stem cells (HSCs) because of its selective expression on progenitor cells and absence on mature hematopoietic cells. Recently we found that CD34 is the prototypic member of a family of three proteins with similar structure and gene organization. In light of this observation, we further examined the distribution of CD34 family members in the mouse.

Materials and Methods

Hematopoietic cell lines and primary tissues were evaluated for CD34 mRNA expression by Northern blot and protein expression by cell surface immunofluorescence. To confirm specific reactivity of the CD34 antibody, cells from CD34-deficient mice were used as controls.

Results

Although CD34 mRNA was undetectable in all murine progenitor cell lines tested, high level expression was detected for bone marrow-derived mast cells (BMMCs). Likewise, cell surface immunofluorescence confirmed that CD34 is expressed by BMMCs and by in vivo peritoneal mast cells. No protein expression was observed for CD34-deficient mast cells. In addition, our data show that mast cells highly express the stem cell antigen Sca-1 and the well-known stem cell and mast cell antigen c-kit.

Conclusions

Our results demonstrate that, contrary to current dogma, CD34 is expressed by one mature hematopoietic lineage: mast cells. Our data also demonstrate that antigenically, murine mast cells and their precursors closely resemble HSCs and suggest caution should be used in the phenotypic characterization of HSCs to prevent mast cell contamination of stem cell preparations.

The Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada

Corresponding Author InformationOffprint requests to: Kelly M. McNagny, Ph.D., Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, V6T 1Z3 Canada

PII: S0301-472X(02)00890-1


View previous. 15 of 16 View next.